The company, “AstraZeneca”, has temporarily stopped the trial of the Corona virus vaccine after an unexplained illness in a volunteer who underwent vaccine tests, according to what was reported by “CNN”.

The company said: “It is a standard precautionary measure in vaccine trials and aims to ensure that the experimental vaccines do not cause dangerous reactions among volunteers.”

The company explained in a statement to CNN: “As part of the ongoing global trials of the Oxford vaccine against Coronavirus, our standard review process has caused the vaccination to stop to allow review of safety data, adding that this is a routine procedure that should occur whenever there is a potential unjustified disease in one of the experiments. During the investigation. ”

The company added: “In large trials, diseases occur by chance but must be independently reviewed to verify this carefully. We are working to speed up individual event review to reduce any potential impact on the schedule. We are committed to participant safety and the highest standards of behavior in our experiments.”

Earlier, AstraZeneca joined eight other companies in signing a pledge in which they pledged not to seek early government approval for any vaccine for the Coronavirus, and they promised that they would wait until they had sufficient data to show that any potential vaccine works safely to prevent infection.

The AstraZeneca vaccine is one of three late-stage coronavirus vaccines in Phase 3 trials in the United States.

It was not immediately clear whether the pause included only US experimental sites or all of the company’s experimental sites around the world, and the Data and Safety Monitoring Board usually monitors experiments for side effects and can order the trial to be halted or stopped.

A spokesman for the company “AstraZeneca” later said that the disease affected a participant in Britain, but said that all the company’s trials of the vaccine worldwide would be stopped temporarily.

The World Health Organization had high hopes for this vaccine, which is one of nine in Phase III trials.